Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma

Patients with BRAF(V600E)-mutant melanoma are effectively treated with the BRAF-inhibiting drug, vemurafenib, but soon develop drug resistance, limiting vemurafenib’s therapeutic efficacy. Constitutive activation of STAT3 in cancer cells and immune cells in the tumor microenvironment (TME) is a cruc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Woo, Kim, Yujin, Keum, Hyeongseop, Jung, Wonsik, Kang, Minho, Jon, Sangyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218293/
https://www.ncbi.nlm.nih.gov/pubmed/35784401
http://dx.doi.org/10.1016/j.omto.2022.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218293/
https://www.ncbi.nlm.nih.gov/pubmed/35784401
http://dx.doi.org/10.1016/j.omto.2022.06.001

Ejemplares similares